GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (STU:PCBK) » Definitions » Gross-Profit-to-Asset %

Sesen Bio (STU:PCBK) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sesen Bio's annualized Gross Profit for the quarter that ended in Dec. 2022 was €0.00 Mil. Sesen Bio's average Total Assets over the quarter that ended in Dec. 2022 was €190.15 Mil. Therefore, Sesen Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 0.00%.


Sesen Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Sesen Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Gross-Profit-to-Asset % Chart

Sesen Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 9.06 14.96 19.28

Sesen Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.25 - - 87.74 -

Competitive Comparison of Sesen Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sesen Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sesen Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sesen Bio's Gross-Profit-to-Asset % falls into.



Sesen Bio Gross-Profit-to-Asset % Calculation

Sesen Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=37.76/( (213.061+178.58)/ 2 )
=37.76/195.8205
=19.28 %

Sesen Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2022 )/( (Total Assets (Q: Sep. 2022 )+Total Assets (Q: Dec. 2022 ))/ count )
=0/( (201.721+178.58)/ 2 )
=0/190.1505
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Sesen Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sesen Bio (STU:PCBK) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (STU:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor 02-22-2010